Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 7/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.31 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111243 | 0.85 | UTS2R (0.36) | ELANESMN1; SMN2HTT | |
| SCHEMBL4724016 | 0.83 | HCAR3 (0.35) | HTT | |
| SCHEMBL4764157 | 0.80 | — | — | |
| SCHEMBL4721464 | 0.79 | ELANE (0.39) | ELANESMN1; SMN2HTT | |
| SCHEMBL4721466 | 0.77 | ELANE (0.38) | ELANESMN1; SMN2HTT | |
| SCHEMBL4722845 | 0.73 | — | — | |
| SCHEMBL4724154 | 0.72 | HCAR3 (0.37) | KMT2ATRPM8 | |
| SCHEMBL16295671 | 0.70 | — | — | |
| SCHEMBL4723841 | 0.70 | HRH3 (0.36) | KMT2A | |
| SCHEMBL18964100 | 0.69 | TRPM8 (0.37) | KMT2ATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0937078-B1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXOSMITHKLINE SPA (IT) | 2003-02-12 | — | — | EP | claimed |
| US-20010047094-A1 | Tricyclic carbapenem compounds | GLAXO WELLCOME SPA | 2001-11-29 | — | — | US | claimed |
| EP-0937078-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.p.A. (IT) | 1999-08-25 | — | — | EP | claimed |
| WO-1998021210-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.P.A. (IT) | 1998-05-22 | — | — | WO | claimed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-6531466-B2 | E.g., a 1-aza-10-(1-hydroxyethyl-11-oxo-4-(het-methylene)-tricyclo(7.2 .0.0(3,8))undec-2-ene-2-carboxylate; good activity against grampositive bacteria such as methicillin-resistant Staphylococcus aureus and epidermidis | GLAXOSMITHKLINE SPA (IT) | 2003-03-11 | — | — | US | disclosed |
| EP-0937078-B1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXOSMITHKLINE SPA (IT) | 2003-02-12 | — | — | EP | disclosed |
| EP-1275301-A1 | Trisubstituted heterocyclic compounds and their use as fungicides | Bayer CropScience S.A. (FR) | 2003-01-15 | — | — | EP | disclosed |
| US-20010047094-A1 | Tricyclic carbapenem compounds | GLAXO WELLCOME SPA | 2001-11-29 | — | — | US | disclosed |
| EP-0937078-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.p.A. (IT) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998021210-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.P.A. (IT) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047094-A1 | Tricyclic carbapenem compounds | OXA1L, GNE, MGAM | GBA1 2820/4885ELANE 582/4885KMT2A 1665/4885 |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | GBA1 3649/4885ELANE 2494/4885KMT2A 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.